Target intelligence / Profile preview

Enamelin (ENAM)

Target
ENAM
Molecular classification
Secretory calcium-binding phosphoprotein (SCPP) family, Enamel matrix protein (EMP) family, Structural matrix protein (non-enzymatic)
01

Overview

Enamelin is a large (approximately 168 kDa) non-amelogenin enamel matrix protein encoded by the ENAM gene and is essential for the proper formation of dental enamel during tooth development. It is the least abundant among enamel matrix proteins (1-5%), but it is critical for controlling the growth, elongation, and architecture of enamel crystals by interacting with hydroxyapatite and other matrix proteins in developing teeth. Enamelin undergoes extensive post-translational modification, including phosphorylation by FAM20C, and is processed by proteases such as MMP20 shortly after secretion. Mutations in the ENAM gene cause autosomal-dominant and autosomal-recessive forms of amelogenesis imperfecta, characterized by generalized thin enamel or absence of the enamel layer. It is not considered a typical drug target, enzyme, transporter, or receptor, but rather a highly specialized extracellular matrix protein essential for hard tissue mineralization in teeth.

Other names
ENAMADAIAI1CAIH2amelogenesis imperfecta 2hypocalcification (autosomal dominant)enamelin
02

Biological functions

Structural component of enamel matrixRegulation of enamel crystal elongation and mineralizationAdhesion of ameloblasts to enamel surface during secretion phaseBinds hydroxyapatite and promotes crystallite formationModulates de novo mineral formation in enamel
03

Disease associations

Amelogenesis imperfecta (especially hypoplastic type, both autosomal dominant and recessive forms)Enamel hypoplasia
04

Safety considerations

Mutations in the ENAM gene disrupt dental enamel formation, but no safety concerns for therapeutics as enamelin is not a direct therapeutic target; gene defects cause heritable enamel thickness defects
05

Biomarkers

*ENAM* gene mutation status is a biomarker for certain subtypes of amelogenesis imperfecta

Beyond the preview

Go deeper on Enamelin (ENAM).

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Drug pipeline

Full profile access

Explore the programs pursuing this target and their development progress.

  • Drug candidates
  • Developers
  • Development stage

Clinical trials

Full profile access

Follow the clinical studies evaluating therapies directed at this target.

  • Trial design
  • Status
  • Readouts

Competitive landscape

Full profile access

Compare approaches across drug candidates, modalities, and indications.

  • Programs
  • Modalities
  • Indications

Literature & evidence

Full profile access

Investigate the research and source evidence behind target biology and development.

  • Publications
  • Sources
  • Analysis

Patents

Full profile access

Explore patent activity around therapies and technologies addressing this target.

  • Patents
  • Assignees
  • Technologies

Research & analysis

Full profile access

Connect target biology, drug development, and emerging evidence in your research.

  • Biology
  • Development news
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on Enamelin (ENAM).

Explore the full profile

Gosset Free

Get started with Gosset.

Enter your work email and we’ll be in touch with next steps.

Work email preferred.

Book a call